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Summary		Select	 lectins	have	powerful	 antiviral	 properties	 that	 effectively	neutralize	HIV-1	by	 targeting	the	dense	glycan	shield	on	the	virus.	Here,	we	reveal	the	mechanism	by	which	one	of	the	most	potent	 lectins,	 BanLec,	 achieves	 its	 inhibition.	We	 identify	 that	BanLec	 recognises	 a	 subset	 of	high-mannose	glycans	via	bidentate	interactions	spanning	the	two	binding	sites	present	on	each	BanLec	monomer	that	were	previously	considered	separate	carbohydrate	recognition	domains.	We	show	that	both	sites	are	required	for	high-affinity	glycan	binding	and	virus	neutralization.	Unexpectedly	 we	 find	 that	 BanLec	 adopts	 a	 tetrameric	 stoichiometry	 in	 solution	 where	 the	glycan	binding	sites	are	positioned	to	optimally	target	glycosylated	viral	spikes.	The	tetrameric	architecture,	 together	 with	 bidentate	 binding	 to	 individual	 glycans,	 leads	 to	 layers	 of	multivalency	 that	drive	viral	neutralization	 through	enhanced	avidity	effects.	These	structural	insights	 will	 prove	 useful	 in	 engineering	 successful	 lectin	 therapeutics	 targeting	 the	 dense	glycan	shield	of	HIV.	
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Introduction	An	 estimated	 37	million	 people	worldwide	 are	 HIV	 positive,	 with	 the	majority	 living	 in	 sub-Saharan	Africa	where	infection	rates	disproportionately	affect	women	due	to	gender	inequality	and	 social	 norms	 restricting	 intervention	 practices	 (2011).	 	 Eradicating	 HIV	 will	 therefore	require	 parallel	 interventions	 to	 limit	 viral	 transmission,	 including	 physical	 barrier	methods,	anti-retrovirals,	 and	 continuing	 vaccine	 development,	 as	 well	 as	 social	 and	 behavioural	education	(Ananworanich	and	Fauci,	2015;	Burton	et	al.,	2012;	François	and	Balzarini,	2012).	A	key	role	 in	this	battle	will	 likely	be	played	by	HIV	microbiocides,	agents	that	act	to	reduce	the	infectivity	 of	 the	 virus	 during	 sexual	 contact	 (Brichacek	 et	 al.,	 2013).	 Lectins	 have	 recently	emerged	 as	 attractive	 microbiocide	 candidates	 which	 could	 be	 applied	 topically	 or	 even	produced	in	situ by engineered commensal microbes (Lagenaur	et	al.,	2015),	and	work	by	limiting	transmission	at	mucosal	surfaces	(François	and	Balzarini,	2012;	Lagenaur	et	al.,	2015;	Liu	et	al.,	2006).	 Several	 lectins	 have	 potent	 anti-HIV	 properties	 in	 vitro	 and	 are	 therefore	 desirable	starting-points	 for	 development	 (Boyd	 et	 al.,	 1997;	 Francois	 and	 Balzarini,	 2012;	Mori	 et	 al.,	2005;	Swanson	et	al.,	2010;	Xiong	et	al.,	2006).		Env,	 the	viral	spike	of	HIV,	 is	a	trimer	of	hetero-dimers	of	extensively	glycosylated	gp120	and	gp41	subunits	responsible	for	host-cell	recognition	and	fusion	(Julien	et	al.,	2013).	Glycosylation	of	Env	acts	to	form	a	“glycan	shield”	that	impedes	antibody	neutralization	(Dacheux	et	al.,	2004).	However,	infected	individuals	can	develop	broadly	neutralizing	antibodies	(bnAbs)	against	the	virus	some	of	which	specifically	target	the	glycan	surface	(Crispin	and	Doores,	2015;	Ward	and	Wilson,	 2015).	 Discrimination	 of	 the	 bnAbs	 against	 self-recognition	 is	 achieved	 by	 the	 large	proportion	of	high-mannose	glycans	within	the	glycan	shield	(Behrens	et	al.,	2016;	Bonomelli	et	al.,	2011;	Doores	et	al.,	2010;	Pritchard	et	al.,	2015a).	This	arises	because,	while	the	number	of	N-glycosylation	 sites	 varies	 between	 viral	 strains	 (Korber	 et	 al.,	 2001),	 their	 density	 is	consistently	 high	 relative	 to	 human	 glycoproteins	 and	 results	 in	 limited	 cellular	 processing	
(Bonomelli	 et	 al.,	 2011).	 	 As	 a	 result,	 high-mannose	 type	 structures,	 which	 are	 a	 conserved	feature	of	the	virus,	may	be	exploited	in	the	design	of	vaccines,	therapeutics	and	prophylactics	(Burton	et	al.,	2012).		Lectins	are	carbohydrate-binding	proteins	and	several	members	of	the	family	have	been	shown	to	bind	the	HIV	virus	via	 its	surface	glycoproteins,	blocking	glycan-mediated	 interactions	with	the	CD4	receptor	and/or	CCR5/CXCR4	co-receptors	on	host	cells.	One	of	the	most	potent	anti-viral	lectins,	BanLec,	has	been	shown	to	inhibit	HIV	fusion	to	HeLa	cells	with	IC50	values	in	the	low	 nanomolar	 range	 (Swanson	 et	 al.,	 2010).	 Whilst	 N-glycan	 specificity	 has	 been	 well	characterized	for	many	anti-viral	lectins	(Bewley	and	Otero-Quintero,	2001;	Botos	et	al.,	2002;	Koharudin	 and	 Gronenborn,	 2011;	 Moulaei	 et	 al.,	 2010;	 Shenoy	 et	 al.,	 2002)	 there	 is	 not	 an	equivalent	understanding	of	 the	 intermolecular	 interactions	between	BanLec	and	HIV	glycans.	However,	 from	 X-ray	 crystallography	 structures	 it	 has	 been	 suggested	 BanLec	 is	 a	 dimeric	protein	with	each	monomer	 containing	 two	carbohydrate	binding	 sites	 (Meagher	et	 al.,	 2005;	Sharma	and	Vijayan,	2011;	Singh	et	al.,	2004;	Singh	et	al.,	2005).	Crystallography	and	molecular	dynamics	 studies	 have	 reported	 BanLec	 binding	 specificity	 to	 disaccharides	 with	 α-1,3-mannosyl	 linkages	 in	 both	 binding	 sites	 (Sharma	 and	 Vijayan,	 2011),	 and	 BanLec-HIV	recognition	is	expected	via	mannose	epitopes	on	high-mannose	N-glycans.	A	binding	model	was	proposed	 recently	where	 each	 binding	 site	 acts	 independently	 to	 engage	 viral	 carbohydrates	(Swanson	et	al.,	2015),	but	was	not	tested	with	high-mannose	N-glycans.	Protein-carbohydrate	interactions	are	typically	weak,	with	milli-	or	micromolar	affinity	(Weis	and	Drickamer,	1996),	but	 can	 be	 strengthened	 through	multivalent	 interactions	 and	 glycan	 clustering	 (e.g.	 the	 Env	glycan	shield).			In	this	study	we	investigate	BanLec-glycan	recognition	through	a	combination	of	structural	and	functional	 studies,	 and	 provide	 an	 explanation	 for	 the	 extraordinary	 specificity	 and	 anti-viral	activity.	We	propose	a	new	tetrameric	structure	of	BanLec	and	show	that	carbohydrate	binding	
sites	 present	 on	 each	monomer	 are	 not	 independent,	 but	 function	 jointly	 to	 engage	 a	 single,	specific	high-mannose	glycan	which	bridges	both	sites	 simultaneously.	These	key	mechanistic	insights	will	aid	successful	development	of	lectin	therapeutics	with	superior	HIV	neutralization	through	the	modulation	of	multivalent	interactions	to	N-linked	glycans.		
	Results	
BanLec	inhibits	HIV	by	targeting	specific	high-mannose	gp120	glycans	We	first	sought	 to	 identify	 the	gp120	N-glycans	 targeted	by	BanLec.	To	do	 this	we	designed	a	depletion	assay	where	fluorescently	labelled	N-glycans	released	from	HIV	gp120	(JRCSF	strain)	were	incubated	with	increasing	concentration	of	BanLec.	The	unbound	glycans	were	identified	by	 hydrophilic	 interaction	 chromatography-high	 performance	 liquid	 chromatography	 (HILIC-HPLC).	 The	 glycans	 that	 possess	 the	 highest	 affinity	 for	 BanLec	were	 then	 identified	 by	 their	preferential	depletion.				We	 found	 that	 the	 predominant	 N-glycans	 present	 were	 oligomannose	 structures	(MannGlcNAc2,	 n	 =	 5–9,	 referred	 to	 hereafter	 as	 Man5-9)	 with	 Man8	 and	 Man9	 the	 most	abundant,	 in	 agreement	 with	 previous	 data	 (Bonomelli	 et	 al.,	 2011).	 Upon	 the	 addition	 of	BanLec,	 the	abundance	of	Man8	and	Man9	structures,	 and	 to	a	 lesser	extent	Man7,	decreased	considerably	 (Figure	 1A).	 Surprisingly,	 we	 found	 that	 Man5	 and	 Man6	 were	 not	 depleted	despite	 the	 presence	 of	 terminal	 mannose	 epitopes	 which	 have	 previously	 been	 reported	 to	bind	 to	 BanLec	 (Mo	 et	 al.,	 2001;	 Sharma	 and	 Vijayan,	 2011).	 Therefore	 BanLec	 binds	 HIV	primarily	via	the	Man8	and	Man9	glycans	on	Env.		We	 then	 tested	 the	affinity	of	BanLec	 to	Man8/9	glycans	 in	 vivo	 through	a	HIV	neutralization	assay.	 We	 used	 two	 pseudovirus	 strains	 (HIVJRCSF	 and	 HIVBaL)	 produced	 in	 the	 absence	 or	presence	of	kifunensine	(kif)	which	is	a	potent	inhibitor	of	α-mannosidase.	Treatment	with	kif	generates	virions	decorated	predominantly	with	Man8	and	Man9	glycans	(Doores	and	Burton,	2010).	 We	 found	 that	 neutralization	 potency	 was	 considerably	 increased	 against	 kif-treated	virions,	leading	to	IC50	values	an	order	of	magnitude	lower	for	HIVJRCSF	(25	pM)	and	HIVBaL	(35	pM)	 compared	 to	wild-type	HIVJRCSF	 (0.51	 nM)	 and	HIVBaL	 (1.1	 nM)	 virions	 (Figure	 1B).	 This	reveals	that	the	potency	of	BanLec	is	significantly	enhanced	when	the	HIV	envelope	proteins	are	
augmented	 with	 longer	 chain	 high-mannose	 structures,	 specifically	 Man8	 and	 Man9.	 The	difference	 in	 IC50	 between	HIVJRCSF	 and	HIVBaL	 in	 the	presence	of	 kif	 is	 likely	 attributed	 to	 the	increased	 number	 of	 glycosylation	 sites	 on	 HIVBaL	 strains.	 Together,	 the	 depletion-assay	 and	neutralization	 data	 demonstrate	 that	 BanLec	 neutralises	 HIV	 via	 binding	 primarily	 to	 Man9	glycans	on	Env.		To	 characterize	 binding	 to	 longer	 chain	 high-mannose	 glycans	 we	 used	 native	 mass	spectrometry	to	measure	the	stoichiometry	and	affinity	of	binding	of	Man7-9	glycans	to	BanLec.	Although	BanLec	has	been	previously	 reported	 to	be	a	dimeric	protein	 (Meagher	et	 al.,	 2005;	Sharma	and	Vijayan,	 2011;	 Singh	et	 al.,	 2005;	 Swanson	et	 al.,	 2015),	we	 found	 it	 to	 exist	 as	 a	tetramer	 in	 the	mass	 spectrum	 (Figure	2A)	 (further	 discussed	below).	Upon	 incubation	with	Man9	glycans	we	observed	BanLec-glycan	complexes	with	between	one	and	four	Man9	bound	(Figure	1C).	Importantly,	we	observed	no	complexes	with	higher	binding	stoichiometries	(even	in	the	presence	of	25	equivalents	of	glycan),	suggesting	BanLec-glycan	binding	stoichiometry	is	1	(glycan):1	(subunit).			We	 then	 calculated	dissociation	 constants	 (Kd)	 for	Man9	binding	 to	BanLec	by	measuring	 the	relative	intensity	of	bound	species	at	different	glycan	concentrations	(Figure	12A-C).	We	found	that	the	Kd	for	all	four	binding	events	of	Man9	to	BanLec	are	similar,	with	an	average	value	of	7.6	±	1.0	µM	(Figure	1D).	Performing	the	same	binding	experiments	with	Man8	and	Man7	showed	that	these	glycans	had	the	same	binding	stoichiometry	with	average	Kds	of	3.8	±	0.8	µM	and	39	±	7.5	 µM	 for	 Man8	 and	 Man7	 respectively.	 These	 binding	 affinities,	 which	 are	 an	 order	 of	magnitude	 lower	 for	 Man7	 than	 for	 Man8	 and	 Man9,	 are	 consistent	 with	 the	 results	 of	 the	depletion	 assay.	Notably,	 for	 all	 three	 glycans,	 each	 successive	 binding	 event	 has	 a	 similar	Kd	implying	there	is	no	cooperativity	in	binding.	
	
Structural	model	of	the	BanLec	tetramer	
Native	 mass	 spectrometry	 revealed	 BanLec	 is	 a	 tetrameric	 protein	 (with	 no	 other	stoichiometries	observed)	which	was	unexpected	as	previous	reports	suggested	it	 is	a	dimeric	protein	 (Meagher	 et	 al.,	 2005;	 Sharma	 and	 Vijayan,	 2011;	 Singh	 et	 al.,	 2005;	 Swanson	 et	 al.,	2015).	 To	 validate	 our	 observation	 we	 examined	 BanLec	 by	 size-exclusion	 chromatography-multi	 angle	 light	 scattering	 (SEC-MALS).	 In	 agreement	 with	 the	 native	 mass	 spectrometry	experiment	BanLec	eluted	in	a	single	peak	with	a	molar	mass	of	approximately	60	kDa	(Figure	
2B).	We	 conclude	 therefore	 that	 BanLec,	 in	 line	with	 other	members	 of	 the	 jacalin	 family	 of	lectins	(Pratap	et	al.,	2002;	Sankaranarayanan	et	al.,	1996),	assembles	as	a	tetramer	in	solution.			To	ascertain	if	tetramers	observed	by	native	mass	spectrometry	share	a	similar	architecture	to	artocarpin/jacalin	 (jacalin	 family	 lectins)	 or	 an	 asymmetric	 crystal	 form,	we	measured	 small-angle	X-ray	scattering	(SAXS)	of	BanLec.	Comparison	of	the	experimental	SAXS	curve	and	radius	of	 gyration	 with	 theoretical	 scattering	 and	 gyration	 values	 clearly	 indicates	 BanLec	 is	consistently	 tetrameric,	 with	 an	 architecture	 similar	 to	 artocarpin	 and	 jacalin	 (Pratap	 et	 al.,	2002;	Sankaranarayanan	et	al.,	1996)	(Figure	3).			The	assembly	of	BanLec	 in	previous	X-ray	crystal	 structures	 is	a	dimer	and	or	an	asymmetric	tetramer	different	than	that	observed	for	artocarpin	and	jacalin	(Meagher	et	al.,	2005;	Sharma	and	Vijayan,	2011;	Singh	et	al.,	2004;	Swanson	et	al.,	2015).	Using	our	preparation	of	BanLec,	which	we	knew	to	be	 tetrameric	 in	solution,	we	solved	a	crystal	structure	of	BanLec	 in	a	new	crystallisation	 condition.	 This	 crystal	 form	was	 equivalent	 to	 existing	 structures	 (Figure	 4A,	
Table	1)	with	the	arrangement	of	the	dimer	similar	to	other	BanLec	structures	(RMSD	values	of	0.475	 Å	 PDB	 2BMY,	 0.464	 Å	 (PDB	 3MIT),	 0.464	 Å	 and	 0.505	 Å	 (PDB	 4PIF),	 and	 likewise	 the	presence	 of	 asymmetric	 tetramers	 in	 the	 crystal	 packing	 (Figure	 S2)	 (Meagher	 et	 al.,	 2005;	Singh	et	al.,	2005;	Swanson	et	al.,	2015).		
Furthermore,	 different	 tetramer	 forms	 could	 be	 distinguished	 by	 ion	 mobility-mass	spectrometry	 (IM-MS)	and	correlated	 to	 the	SAXS	density	envelope	 (Figure	4B	and	4C).	Two	symmetric	BanLec	tetramer	models	were	generated	by	aligning	two-copies	of	the	dimeric	form	with	artocarpin	and	by	independently	docking	two	BanLec	dimers	in	the	SAXS	envelope,	which	had	been	generated	from	an	ab	initio	structural	model	from	the	scattering	data	(Svergun	et	al.,	2001b).	 The	 symmetrical	 tetramer	 created	 from	 independently	 docked	 dimers	 resulted	 in	 a	higher	cross-correlation	coefficient	(CCC)	than	any	other	model	and	represented	the	best	fit	to	the	SAXS	density	envelope.	Using	IM-MS,	the	rotationally	averaged	collision	cross-section	(CCS)	was	 measured,	 which	 represents	 the	 size	 and	 shape	 of	 the	 protein.	 The	 CCS	 of	 BanLec	 was	similar	to	theoretical	CCSs	for	both	symmetric	BanLec	models	and	significantly	different	to	that	of	 the	 asymmetric	BanLec	 tetramer.	The	 combined	SAXS	 and	 IM-MS	data	 therefore	 support	 a	symmetrical	 model	 of	 BanLec	 tetramers,	 in	 which	 the	 architecture	 is	 the	 same	 as	 other	members	 of	 the	 jacalin	 family	 of	 lectins	 (Pratap	 et	 al.,	 2002;	 Sankaranarayanan	 et	 al.,	 1996)	rather	than	the	asymmetric	crystal	form.				We	then	explored	whether	the	tetrameric	architecture	of	BanLec	is	important	for	HIV	inhibition.	A	variant	of	BanLec	(Y46K)	has	been	reported	to	reduce	tetrameric	formation	observed	in	the	crystal	 packing	 (Swanson	 et	 al.,	 2015),	 and	 consistent	with	 this,	 in	 our	model	 this	 residue	 is	located	in	the	tetrameric	interface	(Figure	4E).	By	native	MS	this	variant	is	approximately	50%	dimer/tetramer,	 and	 has	 noticeably	 diminished	 ability	 to	 neutralize	 pseudovirus	 strains	compared	to	wild-type	BanLec	(Figure	4D,	F).	The	IC50	values	for	this	variant	were	2.9	nM,	4.0	nM,	0.6	nM,	and	0.6	nM	for	HIVJRCSF,	HIVBaL,	HIVJRCSF+kif	and	HIVBaL+kif	 respectively.	These	values	are	 5-,	 3-,	 >24-,	 and	 >77-fold	 greater	 than	 for	 wild-type	 BanLec.	 Therefore,	 the	 tetrameric	architecture	of	BanLec	is	essential	for	the	high	potency	observed	against	HIV.		
	
BanLec	binds	high-mannose	glycans	via	bidentate	interactions	
Notably,	 in	 the	 symmetric	 model	 presented	 here,	 all	 carbohydrate-binding	 sites	 (two	 per	monomer)	 (Meagher	 et	 al.,	 2005)	 are	 on	 the	 exterior	 of	 the	 tetramer.	 The	 sites	 on	 each	monomer	 are	 separated	 by	 40	 Å	 (Figure	 4A)	 and	 are	 well	 positioned	 for	 interacting	 with	multiple	 N-glycans	 simultaneously	 on	 different	 HIV	 trimers.	 This	 arrangement	 may	 help	 to	explain	the	propensity	of	viral	particles	to	become	crosslinked	and	aggregate	(Lusvarghi	et	al.,	2016).	 Consistent	 with	 this	 mode	 of	 action,	 when	we	 incubated	 BanLec	 and	 the	 soluble	 Env	trimer	 mimic	 BG505	 SOSIP.664,	 aggregation	 was	 observed	 by	 negative	 stain	 electron	microscopy	(EM)	(Figure	S3)	(Sanders	et	al.,	2013;	Sanders	et	al.,	2015).		The	 apparent	 number	 of	 glycan	 binding	 sites	 (two	 per	 monomer)	 is	 intriguing,	 because	 the	presence	of	 eight	 independent	binding	 sites	 is	 in	disagreement	with	 four	being	 the	maximum	number	of	high-mannose	glycans	we	were	able	 to	observe	bind	by	native	mass	spectrometry.	This	 raises	 the	possibility	 that	 a	 single	 glycan	 can	bind	 simultaneously	 to	 the	pair	 of	 sites	 on	each	monomer.			To	 investigate	 whether	 a	 single	 glycan	 binding	 interaction	 could	 involve	 both	 sites	 on	 each	monomer	we	performed	molecular	dynamics	(MD)	simulations	(Tessier	et	al.,	2013b)	to	sample	sterically	 allowed	 configurations	 of	 glycan	 binding.	 Initially,	 we	 performed	 simulations	 of	 a	small	trisaccharide	(Manα1-2Manα1-3Manα)	bound	to	each	binding	site	present	on	the	BanLec	monomer,	and	found	that	each	site	had	a	similar	binding	strength	using	per-residue	MM-GBSA	calculations	 (Table	 S1).	 We	 then	 performed	 simulations	 of	 Man9	 binding	 to	 BanLec	 to	determine	whether	two	arms	of	the	glycan	structure	could	bind	simultaneously	to	both	glycan	binding	sites	on	each	monomer.			We	uncovered	seven	unique	bidentate	interaction	modes	(Figure	5).	Six	of	these	modes	involve	the	terminal	Manα1-2	residue	(termed	here,	residue	g)	on	the	D1-arm	of	Man9,	suggesting	that	binding	is	regulated	by	the	ability	of	 larger	high-mannose	glycans	(i.e.	Man7-9)	to	bridge	both	
binding	 sites	 simultaneously.	 Using	 the	 same	 per-residue	 MM-GBSA	 molecular	 dynamics	analysis	 we	 calculated	 the	 Man9	 binding	 energies	 for	 each	 mode	 (Table	 S2).	 Amino	 acids	contributing	to	hydrogen	bonding	to	mannose	(site	I:	D133	and	site	II:	D38)	as	observed	from	crystallography	 studies	were	 also	 identified	 in	 this	 analysis	 (Meagher	 et	 al.,	 2005).	 However,	other	 residues	 (G129,	 K130	 and	 F131)	 located	 between	 each	 carbohydrate	 binding	 site	 also	appear	to	equally	contribute	to	Man9	binding.	 Interestingly,	we	consistently	observed	binding	energy	 contributions	 from	 F131.	 This	 residue	 is	 positioned	 between	 the	 glycan	 binding	 sites	suggesting	it	may	interact	with	a	significant	portion	of	the	bound	Man9.			To	 validate	 a	 bidentate	 model	 of	 binding	 we	 created	 mutations	 (D38G	 and	 D133G)	 in	 each	binding	site	of	two	residues	that	hydrogen	bond	to	a	mannose	monosaccharide	(Meagher	et	al.,	2005)	 and	 that	 also	 bind	 to	 Man9	 in	 our	 simulations	 (Figure	 6A).	 We	 then	 recorded	 mass	spectra	of	both	variants,	in	which	the	proteins	were	tetrameric,	and	structurally	unperturbed	as	suggested	by	identical	charge-state	distributions	to	the	wild-type	protein.	We	then	mixed	each	variant	with	two	equivalents	of	Man9	and	compared	the	mass	spectra	to	those	obtained	for	the	wild-type	protein	in	the	same	conditions	(Figure	6B).	Under	these	conditions	wild-type	BanLec	bound	up	 to	 three	Man9	glycans	per	 tetramer,	 for	both	variants	no	 significant	glycan	binding	was	 detected.	 Consistent	 with	 an	 important	 role	 in	 glycan	 binding,	 the	 D38G	 and	 D133G	variants	possess	no	neutralization	activity	 toward	HIV	pseudovirions	 (Figure	6C).	D133G	has	previously	been	shown	to	abolish	HIV	neutralization	(Swanson	et	al.,	2015)	but	D38G	has	not	been	 previously	 tested.	 We	 also	 characterised	 the	 behaviour	 of	 a	 variant	 of	 F131,	 a	 residue	located	in	the	‘saddle’	between	D38	and	D133,	which	also	under	these	conditions	did	not	bind	Man9	and	for	which	HIV	neutralization	was	abolished.			Interestingly,	when	we	 tested	 the	 binding	 of	Man9	 to	 another	 variant,	H84T,	which	 has	 been	reported	 to	 have	 reduced	 multivalent	 interactions	 (Swanson	 et	 al.,	 2015),	 the	 binding	 was	similar	to	wild-type	BanLec.	A	maximum	of	four	Man9	glycans	could	be	observed	bound,	with	an	
average	Kd	of	9.5	±	1.1	µM	(Figure	S1D).	This	 is	 in	contrast	 to	the	report	by	Swanson	et	al.	of	weakened	 affinity	 to	 dimannoside	 carbohydrates	 (Swanson	 et	 al.,	 2015).	 The	H84T	mutation	was	proposed	 to	disrupt	 “the	wall	 that	helps	 create	 the	 two	 independent	 sugar-binding	sites”	(Swanson	 et	 al.,	 2015)	 thus	 reducing	 multivalent	 interactions	 to	 N-glycans.	 Surprisingly,	 we	observed	diminished	HIV	neutralization	with	H84T	variants	with	IC50	of	46.7	nM	(HIVJRCSF),	46.8	nM	(HIVBaL)	1.7	nM	(HIVJRCSF+kifunensine),	and	1.1	nM	(HIVBaL+kifunensine).	These	results	also	contradict	the	 reports	 of	 Swanson	 et	 al.	 in	 which	 H84T	 has	 equal	 neutralization	 ability	 as	 wild-type	BanLec.			In	 summary,	 these	 results	 demonstrate	 that	 BanLec	 inhibits	 HIV	 through	 binding	 of	 Man7-9	glycans	on	 gp120,	 and	while	 each	high-mannose	 glycan	 interacts	with	both	binding	 sites	 in	 a	monomer,	 the	 two	 sites	 are	 not	 redundant,	 but,	 rather,	 are	 both	 necessary	 for	 competent	binding	and	HIV	neutralization.		
Discussion	How	lectins	achieve	their	extremely	high	potency	and	breadth	of	neutralization	to	HIV,	as	well	as	other	enveloped	viruses	 including	Ebola	 (Barrientos	et	al.,	2003)	and	 influenza	 (O'Keefe	et	al.,	 2003),	 has	 been	 an	 important	 question	 in	 the	 field.	 N-linked	 glycan	 recognition	 has	 been	reported	for	other	anti-HIV	lectins	(Botos	et	al.,	2002;	Moulaei	et	al.,	2010;	Sato	et	al.,	2011),	but	no	equivalent	observation	had	been	made	 for	BanLec.	For	potent	neutralization,	a	 lectin	must	exhibit	high	affinity	and	tight	binding	to	the	target	viral	spike	to	account	for	the	nanomolar	IC50	values	 reported.	 However,	 the	 extant	 biophysical	 understanding	 of	 BanLec	 (Weis	 and	Drickamer,	 1996)	 describes	 protein-monosaccharide	 interactions	 six	 or	 more	 magnitudes	greater	than	this,	which	would	be	seemingly	too	weak	to	account	for	the	anti-viral	activity.	To	address	this	question	we	used	a	variety	of	biophysical	approaches	to	unravel	the	precise	nature	of	the	interactions	between	BanLec	and	the	HIV	virus.		
Through	a	combination	of	HPLC	glycan-depletion	and	HIV	neutralization	assays	we	discovered	that	 BanLec	 binds	 only	 to	 Man7-9	 structures,	 which	 typically	 represent	 >50%	 of	 the	 glycan	shield	 (Pritchard	 et	 al.,	 2015b).	 These	 results	 refine	 the	 broader	 specificity	 established	 in	previous	lectin	assays	(Kanagawa	et	al.,	2014;	Singh	et	al.,	2005;	Swanson	et	al.,	2015).	By	native	MS	we	demonstrated	that	BanLec	is	a	tetramer	in	solution,	and	by	exploiting	the	ability	of	the	technique	 to	monitor	 individual	 binding	 stoichiometries	 (Hilton	 et	 al.,	 2013),	 found	 that	 each	monomer	 is	 capable	 of	 binding	 only	 a	 single	 high-mannose	 N-linked	 glycan.	 We	 further	quantified	 Man7-9	 Kds	 to	 be	 in	 the	 low	 micromolar	 range,	 approximately	 three	 orders	 of	magnitude	 lower	 than	 for	 small	 mannose	 sugars	 (Mo	 et	 al.,	 2001).	 By	 performing	molecular	dynamics	 simulations	 on	Man9	binding	we	 discovered	modes	 by	which	 different	 branches	 of	large	multi-antennary	glycans	can	interact	with	a	pair	of	sites	on	a	BanLec	monomer,	which	we	could	 validate	 with	 native	 MS	 binding	 assays.	 This	 bidentate	 binding	 would	 account	 for	 the	much	 lower	Kd	 of	 the	 large	antennary	glycans	 compared	 to	 for	 small	 oligosaccharides,	 due	 to	avidity	effects	of	a	single	N-glycan.	The	avidity	enhancement	ratio	(β)	of	103	is	in	line	with	other	bivalent	interactions	described	in	the	literature	(Mammen	et	al.,	1998).		However,	although	to	some	extent	explaining	the	strong	 interaction	between	BanLec	and	HIV,	this	 intra-subunit	 mechanism	 does	 not	 fully	 account	 for	 viral	 inhibition	 at	 nanomolar	concentrations.	An	explanation	for	this	discrepancy	comes	from	our	discovery	that	BanLec	is	a	tetramer	 in	 solution,	 rather	 than	 a	 dimer	 as	 previously	 thought.	 Our	 (symmetric)	 structural	model	of	BanLec	resembles	other	tetrameric	members	of	the	jacalin	family	of	lectins	and	not	the	asymmetric	 BanLec	 tetramer	 frequently	 observed	 in	 crystal	 structures	 of	 the	 protein.	 The	symmetric	 model	 shows	 that	 the	 glycan	 binding	 sites	 are	 located	 at	 the	 four	 corners	 of	 the	tetramer	 allowing	 the	 lectin	 to	 bind	 Env	 glycans	 with	 minimal	 steric	 hindrance.	 As	 a	 result,	BanLec	should	be	considered	as	a	 tetravalent	 ligand	for	 the	HIV	virion,	with	each	binding	site	facilitating	a	strong	bidentate	interaction	with	high-mannose	glycan.			
We	also	found	that	each	glycan	binding	site	is	not	partitioned	as	has	been	proposed	(Swanson	et	al.,	2015),	but	are	all	equally	essential	for	single	glycan	recognition.	Notably	the	potency	of	the	H84T	variant,	which	was	reported	to	maintain	anti-viral	properties	(Swanson	et	al.,	2015),	was	notably	 less	 in	 our	 hands.	 Disruption	 of	 tetramer	 assembly	 via	 the	 Y46K	 mutation	 reduces	neutralization	 potency	 and	 highlights	 the	 importance	 of	 a	 tetrameric	 stoichiometry	 for	 anti-viral	activity.	These	layers	of	multivalency	appear	to	amplify	each	other	leading	to	the	enhanced	binding	of	single	mannose	moieties	by	a	β factor	of	106.	The	neutralization	of	HIV	is	therefore	able	to	be	achieved	at	nanomolar	concentrations	of	BanLec.		The	ability	of	BanLec	to	bind	to	high-mannose	glycans	presented	across	the	surface	of	the	viral	spike	underpins	both	the	breadth	of	viral	neutralization	and	 its	ability	 to	recognise	glycans	of	multiple	 bnAb	 epitopes.	 Furthermore,	 the	 large	 separation	 between	 binding	 sites	 on	 BanLec	likely	allows	for	the	recognition	of	gp120	glycan	clusters	(Pritchard	et	al.,	2015a),	and	raises	the	possibility	that	the	lectin	bridges	virion	spikes.	Evidence	for	this	comes	from	our	observation	of	extensive	aggregation	when	soluble	mimics	of	 the	viral	spike	are	 incubated	with	BanLec.	This	broad	 and	 versatile	 nature	 of	 interaction	 explains	 the	 general	 potency	 across	 HIV	 strains	through	 specific	 recognition	 of	 conserved	 high-mannose	Env	 glycans,	 only	 elements	 of	which	are	 exploited	 by	 individual	 bnAbs.	 In	 addition	 BanLec	 tetramers	 may	 promote	 interactions	between	 Env	 proteins	 which	 then	 could	 obstruct	 initial	 receptor	 recognition	 or	 the	conformational	rearrangements	required	for	fusion	of	the	HIV	virion	with	the	host	membrane.			Recent	 efforts	 have	 established	 lectins	 as	 anti-HIV	 microbicides	 of	 great	 potential	 utility,	however	the	limited	information	on	the	precise	nature	of	the	interactions	between	BanLec	and	gp120	N-glycans	has	hampered	protein-engineering	strategies.	The	detailed	understanding	we	have	developed	here,	 regarding	both	 the	native	glycan	 targets	and	 their	binding	mechanisms,	will	greatly	inform	future	developments	of	successful	lectin-based	anti-viral	therapies.			
	Accession	codes	Coordinates	and	structure	factors	have	been	deposited	in	the	Protein	Data	Bank	under	accession	code	PDB	5EXG.	
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Figure	Legends	
Figure	 1:	 N-glycan	 binding	 assays	 to	 BanLec	 and	 inhibition	 assays.	 (A)	 HPLC	 depletion	assay	of	released	gp120	N-glycans	incubated	with	0,	1,	5,	10,	20,	50	µM	BanLec.	(B)	Inhibition	of	HIV	pseudovirus	strains	JRCSF	and	Bal	expressed	with	and	without	kifunensine	(kif).	(C)	Native	mass	spectra	of	BanLec	with	different	concentrations	of	Man9	(0,	2.5,	7.5,	15,	30,	50	µM).	 (D)	Dissociation	constants	calculated	from	native	mass	spectrometry	experiments	binding	Man7-9	to	BanLec	calculated	from	peak	intensities.		
Figure	2:	Mass	measurements	of	BanLec.	(A)	Native	mass	spectrum	of	BanLec	with	a	mass	of	59394	Da.	 (B)	 Size-exclusion	 chromatography	multi-angle	 light	 scattering	 of	 BanLec	with	 the	MALS	trace	(black)	indicating	a	molar	mass	of	~60kDa.		
Figure	3:		Small	angle	X-ray	scattering	of	BanLec.	Structure	of	experimental	BanLec	tetramer	(grey)	 and	 theoretical	 SAXS	 curves	 of	 jacalin	 tetramer	 (green),	 artocarpin	 tetramer	 (red)	 and	BanLec	dimer	 (yellow).	Radius	 of	 gyration	 values	 (Rg)	 of	 experimental	Banlec	 and	 theoretical	values	calculated	from	Banlec	(dimer),	jacalin,	artocarpin	crystal	structures	are	shown.			
Figure	 4:	 BanLec	 tetramer	 model	 generated	 from	 SAXS	 and	 native	 MS.	 (A)	 Crystal	structure	 of	 BanLec	with	mannose	molecules	 (green,	 sticks)	 superimposed	 from	 PDB	 1X1V.	Each	 of	 the	 two	 carbohydrate	 binding	 domains	 present	 per	 monomer	 are	 labelled	 (site	 I:	purple,	 site	 II:	 blue).	 (B)	 Experimental	 CCS	 (grey),	 and	 theoretical	 CCS	 of	 artocarpin	 (red),	symmetric	BanLec	model	(yellow),	asymmetric	tetramer	(blue).	Error	bars	are	from	3	repeats	averaging	over	3	charge	states.	 	(C)	SAXS	density	envelope	with	asymmetric	BanLec	tetramer	(blue),	 symmetrical	 model	 obtained	 aligning	 two	 BanLec	 dimers	 onto	 artocarpin	 tetramer	(red)	 and	 two	 independent	 BanLec	 dimers	 (symmetrical	 tetramer	 (yellow))	 fitted	 into	 the	density.	 	 CCC:	 Cross-correlation	 coefficient.	 (D)	 Intact	 mass	 spectrum	 of	 Y46K	 BanLec.	 Two	balls:	dimer	charge	series;	four	balls:	tetramer	charge	series.	(E)	Symmetrical	tetramer	model	with	 tyrosine	 (Y46)	 residues	 located	 in	 the	 tetrameric	 interface.	 (F)	 Neutralization	 assay	 of	BanLec	 Y46K	 against	 HIV	 pseudovirus	 strains	 JRSCF	 and	 Bal	 expressed	 with	 and	 without	kifunensine	(+kif).	
	
Figure	 5:	 	 Seven	 predicted	 bidentate	 binding	 modes	 of	 Man9	 to	 BanLec.	 Cartoon	representation	 of	Man9	 is	 shown	 in	with	D1,	D2	 and	D3	 arms	 of	 the	 structure	 indicated.	 The	individual	 residues	 of	Man9	 are	 indicated	with	 letters	 a-k	 and	 coloured	 residues	 are	 used	 to	clarify	monosaccharide	binding	to	BanLec.	The	particular	Man9	residues	bound	in	each	binding	site	 of	 the	 BanLec	 monomer	 are	 indicated	 in	 each	 image.	 An	 arrow	 points	 from	 the	 residue	bound	in	Site	II	(D38)	to	the	residue	bound	in	Site	I	(D133).		
	
Figure	 6:	 	 HIV	 neutralisation	 and	 glycan	 binding	 to	 BanLec	 variants.	 (A)	 Molecular	dynamics-derived	positions	of	Man9	to	a	single	BanLec	subunit	show	different	glycan	branches	interacting	 simultaneously	 to	 form	 bidentate	 binding.	 BanLec	 is	 shown	 in	 surface	representation	(yellow)	with	residues	contributing	to	glycan	binding	coloured	(D38:	red,	F131:	cyan,	 D133:	 pink,	 H84:	 orange).	 (B)	 Native	 mass	 spectra	 of	 wild-type,	 D38G,	 D133G,	 F131G,	
H84T	variants	with	2	molar	equivalents	Man9	substrate.	Peaks	corresponding	to	BanLec-Man9	complexes	are	independently	coloured.	(C)	HIV	neutralization	assay	of	BanLec	variants	against	JRCSF	and	Bal	strains	expressed	with	and	without	kif.											
Table		Table	1.	Crystal	parameters,	data	collection,	and	refinement	statistics	of	BanLec	
Data	collection	Space	group	 P21212	Cell	dimensions	 	
			a,	b,	c	(Å)	 63.33,	95.98,	47.53				α	=	β	=	γ	(°)	 90	Resolution	(Å)	 19.32–1.70	(1.74–1.70)	*	
Rmeas	 0.137	(1.283)	Mean	I/σI	 15.77	(2.07)	Completeness	(%)	 98.8	(96.5)	Redundancy	 12.5	(12.6)		 	
Refinement	Resolution	(Å)	 19.32–1.70	(1.74–1.70)	No.	reflections	 30,641	
Rwork	/	Rfree		 0.1760	/	0.2062	No.	atoms	 					Protein	 2,091					Ligand/ion	 42					Water	 120	Average	B-factors	 		 				Protein	 19.5					Ligand/ion	 21.7					Water	 26.5	R.m.s.	deviations	 		 				Bond	lengths	(Å)	 0.019		 				Bond	angles	(°)	 1.919		*Numbers	in	parentheses	refer	to	the	relevant	outer	resolution	shell.				
	
	
		
	
	
	
STAR	Methods	
Method	Details	Protein	expression	and	purification		BanLec	 template	 DNA	 based	 on	 the	 reported	 sequence	 from	 Peumans	 et	 al.	 (Peumans	 et	 al.,	2000)	 was	 purchased	 from	 Genscript	 (Piscataway,	 NJ).	 BanLec	 encoding	 DNA	 was	 amplified	using	 a	 Phusion	High-Fidelity	 PCR	 kit	 (New	England	Biolabs)	 and	 restriction	 sites	 for	 BamHI	and	XhoI	were	 introduced	and	the	PCR	product	was	purified	using	a	Qiagen	Gel	Extraction	kit	and	 cloned	 into	 a	 linearized	 pET28	 vector	 (cut	 with	 BamHI	 and	 XhoI)	 containing	 a	 TEV	protease-cleavable	 N-terminal	 polyhistidine	 tag	 using	 In-Fusion	 HD	 Cloning	 Kit	 (Clontech).	Construction	of	 green	 fluorescence	protein	 (GFP)-tagged	BanLec	was	performed	 similarly	but	with	NdeI	and	NheI	specific	inserts	introduced	to	the	PCR	product.	The	PCR	product	was	cloned	into	 a	 linearized	 pET15	 vector	 containing	 a	 TEV-GFP-His	 tag	 on	 the	 C-terminus.	 BanLec	was	transformed	and	expressed	in	E.	coli	BL21	Gold(DE3)	competent	cells	(Agilent)	and	cells	grown	in	LB	media	containing	50	µg/mL	ampicillin	(pET15)	or	25	µg/mL	kanamycin	(pET28)	until	an	OD	of	0.6	was	reached.	Expression	of	BanLec	was	induced	by	the	addition	of	isopropyl-D-thio-galactopyranoside	(IPTG)	to	1	mM,	and	cells	cultured	for	a	further	4	hours	at	37	°C.	Cells	were	pelleted	by	 centrifugation	 at	 5,000	g	 for	 10	min	 and	 lysed	by	use	 of	 a	microfluidiser.	 Soluble	protein	was	 separated	 from	 cell	 debris	 by	 centrifugation	 at	 20,000	g	 for	 20	min.	 The	His-tag	protein	 was	 purified	 from	 the	 lysate	 by	 affinity	 purification	 with	 a	 HisTrap	 HP	 column	 (GE	Healthcare).	 The	 His-tag	 was	 then	 cleaved	 by	 incubation	 with	 tobacco	 etch	 virus	 (TEV)	overnight	at	room	temperature.	The	cleaved	protein	was	purified	by	reverse	Ni-affinity	and	the	
purity	of	the	flow-through	containing	BanLec	was	assessed	by	SDS-PAGE	(Novex	NuPAGE)	prior	to	MS.		HIV	inhibition	assays	Pseudovirus	 was	 generated	 in	 HEK	 293T	 cells	 as	 described	 (Montefiori,	 2005;	 Singh	 et	 al.,	2005).	Briefly,	293T	cells	were	 transfected	with	plasmids	expressing	 the	virus	backbone	PSG-3∆env	and	the	functional	envelope	clone	at	a	ratio	of	2:1	using	PEI	(1	mg/mL,	1:3	PEI:total	DNA,	Polysciences)	according	to	the	manufacturer’s	instructions.	Virus	supernatants	were	harvested	after	 72	h.	 Glycosidase	 inhibitor,	 kifunensine,	was	 added	 at	 the	 time	of	 transfection	 at	 a	 final	concentration	 of	 25	 μM	 (Doores	 and	 Burton,	 2010).	 Neutralization	 activity	 of	 BanLec	 or	 HIV	bnAb	wild-type	and	mutants	against	pseudovirus	in	TZM-bl	cells	was	determined	as	described	previously	(Montefiori,	2005;	Singh	et	al.,	2005).	Briefly,	TZM-bl	cells	were	seeded	in	a	96-well	flat	bottom	plate	and	infected	with	pseudovirus	in	the	presence	of	BanLec	or	HIV	bnAb	(200	μL	total	volume).	Viruses	were	preincubated	with	BanLec	or	HIV	bnAb	for	1	h	at	37	°C.	Luciferase	reporter	 gene	 expression	 was	 quantified	 72	 h	 after	 infection	 upon	 lysis	 and	 addition	 of	luciferase	substrate	(Promega).		bnAb	competition	ELISA	Microtitre	ELISA	plates	(Corning)	were	coated	with	recombinant	gp120JR-CSF	(5	µg/mL	in	PBS)	overnight	at	4	°C.	Plates	were	washed	five	times	with	a	solution	of	PBS	containing	0.05%	Tween	20	(v/v)	and	then	blocked	for	1	h	at	room	temperature	with	5%	non-fat	milk	 in	PBS	+	0.05%	Tween	(blocking	buffer).	Plates	were	emptied	before	addition	of	a	titration	of	BanLec	(starting	concentration,	500	µg/mL	in	blocking	buffer	using	a	1:3	dilution	series)	and	incubated	for	30-60	min.	 HIV	 bnAbs	were	 then	 added	 at	 a	 constant	 concentration	 (Ab	 concentration	 represented	IC50	 and	were	 diluted	 in	 blocking	 buffer)	 and	 incubated	 for	 a	 further	 1.5	 h.	 Plates	were	 then	washed	 (×5)	 and	 alkaline	 phosphatase	 (AP)-conjugated	 goat	 anti-human	 Fab	 secondary	antibody	 (Thermo	 Scientific	 Pierce)	 was	 added	 at	 a	 1:1000	 dilution	 in	 blocking	 buffer	 and	
incubated	for	1	h.	Plates	were	washed	(×5)	and	then	AP	substrate	(50	µL	/	well)	was	added.	The	OD	at	405	nm	was	measured	after	20	min.	
	Glycan	HPLC	
N-glycans	were	released	from	150	μg	recombinant	gp120	(JRCSF)	by	incubation	with	PNGase	F	(New	England	BioLabs)	according	to	manufacturer’s	protocol.	Glycans	were	separated	from	the	protein	by	spin-filtration	through	5000	Da	MWCO	filter	(Vivaspin,	GE	Healthcare)	and	speedvac	dried.	Released	glycans	were	2-AB	 labelled	as	described	previously	 (Struwe	and	Rudd,	2012).	Briefly,	glycans	were	incubated	with	20	μL	1%	formic	acid	for	45	min	at	room	temperature,	and	dried	 before	 addition	 of	 5	 μL	 2-AB	 labelling	 solution	 (DMSO:glacial	 acetic	 acid	 (7:3	 v/v),	 1M	sodium	cyanoborohydride,	0.5	M	anthranilamide	(2-AB)),	 followed	by	incubation	for	3	h	at	65	°C.	Excess	dye	was	removed	by	purification	with	PhyNexus	normal	phase	columns,	equilibrated	with	95%	acetonitrile	and	eluted	with	20%	acetonitrile.	2-AB	labelled	glycans	were	 incubated	with	 BanLec	 for	 1	 h	 at	 37°C	 for	 the	 depletion	 assays.	 Unbound	 2-AB	 labelled	 glycans	 were	separated	from	BanLec-glycan	complexes	using	Vivaspin	500,	5000	Da	MWCO	spin	columns	(GE	Healthcare).	Glycans	were	dried	and	resuspended	 in	30	μL	65%	CAN	prior	 to	analysis	using	a	LudgerSep	N2	amide	HPLC	column	 (Ludger	Ltd).	 	Each	HPLC	 injection	 consisted	of	N-glycans	released	 from	 10	 µg	 gp120.	 Analysis	 was	 performed	 using	 a	 Waters	 Acquity	 system	 with	Empower	software.	
	Native	mass	spectrometry	Initial	stoichiometry	measurements	and	carbohydrate	titration	experiments	were	performed	on	a	 hybrid	 quadrupole	 time-of-flight	 mass	 spectrometer	 modified	 for	 high	 mass	 transmission	(Sobott	 et	 al.,	 2002).	 Conformational	 analysis	 was	 performed	 using	 first	 generation	 Waters	Synapt	IM-MS	instrument,	employing	a	linear	drift	field	to	allow	direct	calculation	of	collisional	cross-sections.	Prior	to	all	MS	analyses,	aliquots	(50	µL)	of	BanLec	were	desalted	using	Bio-spin	6	(Bio-Rad)	centrifuge	columns,	equilibrated	with	200	mM	ammonium	acetate.	Following	buffer	
exchange	 protein	 concentration	 was	 measured	 by	 absorbance	 at	 280	 nm	 using	 a	 UV/Vis	spectrophotometer.	Protein	concentrations	were	then	adjusted	to	between	5	and	10	µM	for	all	MS	 experiments.	 Typically,	 3	 µL	 of	 protein	was	 loaded	 into	 gold-coated	nanospray	 capillaries	prepared	in-house	and	mounted	into	a	static	nanospray	source	block	(Hernandez	and	Robinson,	2007).	Electrospray	was	 induced	by	applying	a	voltage	of	between	1.1–1.3	kV	to	the	capillary.	Backing	pressure	in	the	source	was	raised	to	a	pressure	of	6–7×10-3	mbar	by	‘choking’	the	line	to	the	roughing	pump,	improving	the	transmission	of	high	molecular	weight	ions.	For	unbound	BanLec	 stoichiometry	 measurements,	 sample	 cone	 voltages	 of	 60-80	 V	 were	 used,	 which	provided	efficient	desolvation	and	narrower	peak	widths	but	with	no	evidence	of	any	induced	dissociation.	 During	 titration	 experiments,	 peak	 width	 was	 compromised	 to	 ensure	 no	 gas-phase	 dissociation	 of	 oligomannose	 ligands	 and	 sample	 cone	 was	 maintained	 below	 40	 V	(typically	 20	 V).	 To	 this	 end,	 collision	 energies	 within	 the	 instrument’s	 collision	 cells	 were	maintained	at	the	minimum	values	necessary	for	adequate	transmission.	This	was	deemed	as	10	V	in	the	collision	cell	of	the	q-TOF	and	5	V	in	the	trap	collision	cell	on	the	Synapt.	Transfer	cell	voltages,	which	act	to	provide	the	linear	drift	field	across	the	IMS	cell,	were	varied	over	several	values	to	allow	calculation	of	the	post-IMS	flight	time.		For	 titration	 experiments	 protein	 and	 oligomannose	 aliquots	 were	 prepared	 at	 twice	 the	required	 concentration	 and	 then	mixed	at	 a	1:1	 ratio	 to	 give	 the	desired	 concentration	point.	Oligomannose	 stocks	were	prepared	 to	150	µM	and	diluted	 to	 the	 required	 concentrations	 in	milliQ	 water.	 Protein	 concentrations	 were	 determined	 by	 measuring	 absorbance	 at	 280	 nm.	Titration	experiments	were	performed	at	a	final	ammonium	acetate	concentration	of	100	mM.	Effort	was	made	to	ensure	that	capillary	dimensions	were	kept	constant,	 from	the	same	batch	and	that	spray	was	initiated	from	a	similar	capillary-cone	distance.	Collision	energy	ramps	were	performed	to	demonstrate	that	instrument	conditions	used	during	titrations	did	not	lead	to	any	gas-phase	 dissociation.	 Mass	 spectra	 were	 deconvolved	 using	 UniDec	 into	 zero-charge	 mass	distributions	(Marty	et	al.,	2015).	Using	the	UniDec	Data	Collector	module,	peak	[heights/areas]	
were	extracted	from	the	mass	distributions	and	fit	to	a	binding	model	using	a	least	square	fitting	approach.	The	software	and	links	to	source	code	are	available	at	unidec.chem.ox.ac.uk.			SEC-MALS	Analysis	of	purified	BanLec	was	performed	using	an	Agilent	1260	HPLC	with	an	Agilent	Bio	SEC-3	 SEC	 column	 (4.6×150	mm,	 3	 μm	 particle,	 150	 Å	 pore	 size)	 coupled	 to	 a	 DAWN	HELEOS	 II	scattering	 detector	 (Wyatt	 Technologies)	 and	Optilab	T-rEX	 (Wyatt	 Technologies)	 differential	refractive	 index	 detector.	 The	 MALS	 detector	 was	 equilibrated	 overnight	 to	 ensure	 minimal	background	 light	 scattering.	 Roughly	 50	 μg	 of	 protein	 was	 loaded	 on-column	 (column	compartment	was	set	to	20	°C)	at	a	flow	rate	of	0.8	mL/min	in	150	mM	sodium	phosphate	pH	7.5.	 Data	 acquisition	 and	 analysis	 were	 performed	 with	 Astra	 6.1	 software	 (Wyatt	Technologies).			X-ray	crystallography	BanLec	crystals	were	grown	by	hanging-drop	vapour	diffusion.	A	protein	solution	[10	mg/mL,	in	100	mM	NaCl,	20	mM	Tris	(pH	7.4)]	was	mixed	1:1	(v/v)	with	a	reservoir	solution	containing	0.05	M	NaBr,	 0.1	M	 Bis	 Tris	 and	 19%	PEG-3350	 (pH	 7.5).	 The	 drop	 sizes	were	 1μL,	 and	 the	volume	of	the	reservoir	solution	was	1	mL.	The	crystallisation	trays	were	left	at	20	°C.	Crystals	were	harvested	and	transferred	briefly	into	a	cryoprotectant	composed	of	10%	glycerol	in	the	reservoir	solution.	The	plate-like	crystals	typically	began	to	form	after	24	hours	and	were	fully	formed	 in	 72	hours.	Data	 for	BanLec	were	 collected	 at	Diamond	 Synchrotron	using	 the	 I04-1	beamline	and	were	processed	using	XDS	and	XSCALE.	The	results	are	summarised	in	Table	EV1,	along	with	key	structure	refinement	details.	The	protein	crystallised	in	the	orthorhombic	space	group	P21212	and	diffracted	to	1.70	Å,	with	the	following	unit	cell	dimensions:	a	=	63	Å,	b	=	96	Å,	c	=	48	Å.	Cell	content	analysis	indicated	high	probability	of	two	monomers	of	BanLec	in	the	asymmetric	 unit.	 A	monomer	 of	 BanLec,	 from	PDB	2BMY	 (stripped	 of	 all	 non-protein	 atoms)	was	 used	 as	 a	 search	 molecule	 for	 molecular	 replacement	 using	 Phaser.	 Refinement	 was	
conducted	 with	 Refmac,	 and	 electron	 density	 maps	 were	 analysed	 with	 Coot.	 The	 validation	tools	of	Coot	and	Molprobity	were	used	to	check	for	and	correct	conformational	issues.	
	SAXS	Data	was	collected	at	 the	B21	bending	magnet	 instrument	at	Diamond	Light	Source	 (Harwell,	UK).	Samples	were	prepared	in	200	mM	ammonium	acetate	to	a	concentration	of	8	mg/mL	in	a	96	well	 plate	 at	 5	 °C.	 Protein	 and	 corresponding	 buffer	 solutions	were	 exposed	 to	 the	 beam	using	 an	 Arinax	 (Grenoble,	 France)	 BioSAXS	 automated	 sample	 changer	 robot,	 consisting	 of	temperature	 controlled	 storage	 and	 exposure	 units.	 The	 exposure	 unit	 contained	 a	 1.6	 mm	diameter	 quartz	 capillary	 in	 which	 the	 samples	 were	 illuminated	 with	 the	 X-ray	 beam;	 the	exposure	 unit	 temperature	 was	 set	 to	 15	 °C.	 The	 sample	 capillary	 was	 held	 in	 vacuum	 and	subjected	 to	 a	 cleaning	 cycle	 between	 each	 measurement.	 A	 Pilatus	 2M	 two-dimensional	detector	 was	 used	 to	 collect	 180	 frame	 exposures	 of	 1	 s	 from	 each	 sample	 and	 the	corresponding	buffer.	The	detector	was	placed	at	3.9	m	from	the	sample,	giving	a	useful	q-range	of	 0.012	 Å-1	 <	 0.4	 Å-1,	 where	 q	 =	 4π	 sin(θ)/λ,	 where	 2θ	 is	 the	 scattering	 angle	 and	 λ	 is	 the	wavelength,	which	was	set	to	1	Å.	Two	dimensional	data	reduction	consisted	of	normalisation	for	 beam	 current	 and	 sample	 transmission,	 radial	 sector	 integration,	 background	 buffer	subtraction	 and	 averaging.	 Each	 frame	 was	 inspected	 for	 the	 presence	 of	 radiation	 induced	protein	damage;	 if	 this	was	 found	to	be	the	case,	 the	 frames	were	not	reduced	and	processed.	We	produced	a	bead	model	from	our	BanLec	SAXS	data	using	gasbor	(Svergun	et	al.,	2001a).	The	resulting	model	was	subsequently	transformed	into	a	density	map	using	Situs’	pdb2vol	tool,	and	all	 our	 BanLec	 structural	models	 docked	 in	 it	 using	 Situs’	 colores	 tool	 (Wriggers	 and	 Chacón,	2001).		An	 asymmetrical	 BanLec	 tetramer	 was	 from	 the	 crystal	 packing	 of	 our	 BanLec	 protein	preparation.	We	produced	a	first	BanLec	symmetrical	tetramer	via	a	structural	alignment	of	two	of	our	BanLec	dimers	onto	artocarpin	tetrameric	structure	(pdb:	1J4S).	The	resulting	model	was	
subsequently	 relaxed	with	 2000	 conjugate	 gradient	 steps	 in	 implicit	 solvent	 using	 the	NAMD	(Phillips	et	al.,	2005)	molecular	dynamics	engine	and	the	Amber14SB	(Case	et	al.,	2014)	 force	field.	 We	 produced	 a	 second	 symmetrical	 BanLec	 tetramer	 by	 directly	 docking	 two	 BanLec	dimers	 into	 our	 SAXS	 density	 using	 Situs’	 collage	 tool	 (Birmanns	 et	 al.,	 2011).	 For	 all	 the	atomistic	 models	 detailed	 above,	 the	 SAXS	 signal	 was	 simulated	 using	 crysol	 (Svergun	 et	 al.,	1995),	the	radius	of	gyration	predicted	with	Hydropro	(Ortega	et	al.,	2011),	and	the	collisional	cross-section	calculated	using	Impact	(Marklund	et	al.,	2015).	
	Molecular	grafting	
Trimannose	Structure:	A	model	for	bound	trimannose	oligosaccharide	(Manα1-2Manα1-3Manα)	was	built	by	grafting	(Grant	et	al.,	2014;	Tessier	et	al.,	2013a)	the	required	residues	onto	the	co-crystal	structure	of	Manα	bound	to	BanLec	(PDBID:	2BMZ).	
	
Bidentate	Structure:	The	3D	structure	of	Man9	was	generated	by	grafting	the	required	branches	onto	 the	 bound	 Manα	 in	 PDBID:	 2BMZ.	 For	 grafting,	 initial	 conformations	 for	 Man9	 were	generated	using	GLYCAM-Web	(www.glycam.org).	Structure	modelling	was	used	 to	determine	whether	 Man9	 was	 capable	 of	 adopting	 a	 low	 energy	 conformation	 that	 would	 allow	 two	branches	 of	 the	Man9	oligosaccharide	 to	bind	 simultaneously	 in	 both	binding	 sites	 of	BanLec	(bidentate	 binding).	 A	 bound	 Manα	 residue	 in	 one	 arm	 was	 retained	 in	 the	 crystallographic	orientation,	 while	 the	 intervening	 glycosidic	 torsion	 angles	 were	 varied	 within	 low	 energy	bounds	(±	20°)	(Nivedha	et	al.,	2013).	Any	binding	modes	that	placed	a	Manα	from	a	second	arm	within	 2	 Å	 of	 the	 second	 binding	 site	 were	 retained	 for	 further	 refinement	 by	 energy	minimization	and	molecular	dynamics	(MD)	simulation.	This	procedure	was	applied	to	each	of	the	eight	Manα	residues	in	Man9.	
	
Energy	Minimization	and	MD	simulation		
Bidentate	Co-complexes:	The	MD	simulations	were	performed	using	the	Amber14	software	suite	(Case	et	al.,	2014).	The	Glycam06h	(Kirschner	et	al.,	2008)	and	Amber14SB	(Case	et	al.,	2014)	force	 fields	were	 employed	 for	 carbohydrate	 and	 protein	 respectively.	 Hydrogen	 atoms	were	added	 and	 protonation	 states	 were	 assigned	 via	 tleap	 using	 the	 default	 parameters	 for	Glycam06h	 and	 Amber14SB.	 Energy	 minimization	 was	 performed	 for	 20,000	 steps	 (10,000	steepest	 decent,	 10,000	 conjugant	 gradient).	 Following	minimization,	 the	 system	was	 heated	over	100	ps	from	5	K	to	300	K	and	then	equilibrated	at	300	K	for	300	ps.	During	the	final	200	ps,	distance	restraints	were	introduced	to	guide	the	desired	Manα	residue	into	the	second	binding	site	 (Table	 S3).	 The	 restraints	 were	 then	 turned	 off	 over	 a	 1	 ns	 period,	 and	 the	 simulation	performed	without	any	restraints	for	a	further	10	ns.	Solvation	was	treated	with	the	generalized	Born	approximation	(igb	=	2)	 (Onufriev	et	al.,	2004)	 throughout	with	a	non-bonded	cut-off	of	999	Å.	The	cuda	(Gotz	et	al.,	2012;	Salomon-Ferrer	et	al.,	2013)	module	was	employed	for	the	MD	simulations.	Pressure	and	 temperature	were	regulated	with	a	Berendsen-type	barostat	 (1	ps	constant)	and	Langevin	 thermostat	 (2	ps-1	 collision	 frequency)	 respectively.	Scaling	 factors	for	1-4	electrostatic	and	van	der	Waals	 interactions	were	set	 to	unity	 for	glycans	(Woods	and	Chappelle,	2000),	and	1.2	and	2.0	for	proteins	(Hornak	et	al.,	2006).	Covalent	bonds	to	hydrogen	were	constrained	with	the	SHAKE	algorithm	allowing	a	2	fs	time	step	(Ryckaert	et	al.,	1977).	
	
Trimannose	 Co-complexes:	A	 similar	 protocol	 was	 followed	 for	 simulating	 the	 trimannose	 co-complexes	 with	 the	 following	 variations.	 After	 the	 initial	 minimization,	 the	 structure	 was	enclosed	in	a	box	of	explicit	TIP3P	(Jorgensen	et	al.,	1983)	water,	with	an	8	Å	buffer.	This	system	was	subjected	to	a	second	minimization	round	with	5	kcal/mol/Å2	restraints	on	non-hydrogen	solute	atoms.	A	500	ns	MD	simulation	was	performed	without	distance	or	Cartesian	restraints.	A	non-bonded	interaction	cut-off	of	8	Å	was	applied,	beyond	which	long-range	electrostatics	were	treated	with	the	particle-mesh	Ewald	(PME)	method	(Darden	et	al.,	1993).		
	
Per-residue	 MM-GBSA:	 An	 MM-GBSA	 calculation	 (molecular	 mechanics	 with	 generalised	 Born	and	 surface	 area	 solvation)	 with	 igb=2	 (Onufriev	 et	 al.,	 2004)	 was	 performed	 on	 1,000	snapshots	 taken	 at	 regular	 intervals	 from	 both	 the	 trimannose	 and	 Man9	 simulations.	 The	energies	were	decomposed	on	a	per-residue	basis	(idecomp=1).			CryoEM	
Analysis	of	Lectin-SOSIP	complexes	negative	stain	electron	microscopy	(EM):		 Env	 proteins	 were	prepared	for	negative	stain	EM	analysis	as	previously	described	(Pugach	et	al.,	2015;	Sanders	et	al.,	2013).	Briefly,	a	3	µL	aliquot	containing	0.01-0.05	mg/mL	of	Env	protein	(as	determined	by	UV	A280	using	 the	 theoretical	extinction	coefficient	based	on	peptide	sequence	alone)	or	Env	protein	in	complex	with	lectin	was	applied	for	5	s	onto	a	carbon-coated	400	Cu	mesh	grid	that	had	been	glow	discharged	at	20	mA	for	30	s,	then	negatively	stained	with	nano-W	(Nanoprobes,	USA)	for	about	5	s,	blotted	with	filter	paper,	and	stained	for	another	15	s	with	nano-W.	Nano-W	was	chosen	over	the	more	common	uranyl	salts	due	to	the	more	neutral	pH	of	the	stain,	which	should	prevent	dissociation	between	pH-sensitive	 complexes	 (such	as	Env-ligand	 interactions	that	are	strongly	governed	by	glycans).	Grids	were	screened	to	assess	stain	quality	Data	were	collected	 on	 either	 an	 FEI	 Tecnai	 T12	 electron	 microscope	 operating	 at	 120	 keV,	 with	 an	electron	dose	of	~25	e-/Å2	and	a	magnification	of	52,000×	that	resulted	in	a	pixel	size	of	2.05	Å	at	 the	 specimen	 plane,	 or	 an	 FEI	 Talos	 electron	 microscope	 operating	 at	 200	 keV,	 with	 an	electron	dose	of	~25	e-/Å2	and	a	magnification	of	73,000×	that	resulted	in	a	pixel	size	of	1.98	Å	at	 the	 specimen	 plane.	 Images	were	 acquired	with	 a	 Tietz	 TemCam-F416	 CMOS	 camera	 (FEI	Tecnai	T12)	or	FEI	Ceta	16M	camera	(FEI	Talos)	using	a	nominal	defocus	range	of	1000-1500.	In	the	cases	when	trimers	were	visible	in	the	raw	images,	data	were	processed	using	methods	adapted	 from	 those	 used	 previously	 (Pugach	 et	 al.,	 2015).	 Resulting	 2D	 class	 averages	 were	visually	inspected	for	any	Env-lectin	complexes.		
Analysis	 of	 Lectin-SOSIP	 complexes	 by	 Blue	 Native	 Gel	 Electrophoresis	 (BN-PAGE)	 and	 size-
exclusion	chromatography	(SEC):	Lectin	and	BG505	SOSIP.664	were	combined	at	varying	molar	ratios	(using	the	molecular	weights	of	BG505	SOSIP.664	trimer	and	 lectin	tetramer)	of	0.75:1,	1.5:1,	3.75:1,	 and	7.5:1,	 incubated	at	 room	 temperature	 for	15	min,	 and	 then	 run	on	a	4-16%	BN-PAGE	gel	according	to	manufacturer’s	recommendations.		A	 separate	 Lectin	 and	 BG505	SOSIP.664	 incubated	 sample	 (6:1	 molar	 ratio)	 was	 subjected	 to	 centrifugation	 (14,000	 g,	 10	min,	4	°C)	and	loaded	onto	a	Superose	6	Increase	10/300	column	(GE	Healthcare).	The	higher	molecular	weight	peak,	 corresponding	 to	 the	expected	MW	 for	SOSIP.664	 trimer,	was	pooled,	concentrated,	and	analyzed	by	EM.	
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